Celgene Stock Hits New 52-Week High (CELG)
NEW YORK (
) --
(Nasdaq:
) hit a new 52-week high Wednesday as it is currently trading at $75.62, above its previous 52-week high of $75.11 with 2.3 million shares traded as of 12:25 p.m. ET. Average volume has been 3.4 million shares over the past 30 days.
Celgene has a market cap of $32.86 billion and is part of the
sector and
industry. Shares are up 8.2% year to date as of the close of trading on Tuesday.
Celgene Corporation, an integrated biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases. The company has a P/E ratio of 19.3, below the average drugs industry P/E ratio of 31.1 and above the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Celgene as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full
.
See all
52-week high stocks
or get investment ideas from our
.
null
